Recent Investment Analysts’ Ratings Changes for Intrexon Corporation (XON)
Intrexon Corporation (NYSE: XON) has recently received a number of price target changes and ratings updates:
- 10/16/2017 – Intrexon Corporation was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Intrexon depends largely on ECCs and license and collaboration deals for revenues and any unfavorable outcome from the development of these could be a major setback and hurt its prospects too. Furthermore, shares of the company have underperformed the Medical Services industry in the last one year. However, the company's expanding portfolio of technologies has enabled it to develop a robust pipeline of candidates targeting a broad range of diseases including cancer and others. We are also positive on Intrexon’s efforts to expand through acquisitions, exclusive channel collaborations (ECCs) and joint ventures. Additionally, it announced the formation of a wholly-owned subsidiary-Precigen, Inc. as part of its structural alternatives so that it can take better decisions of its health business. Estimates have been mixed ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in recent quarters.”
- 10/6/2017 – Intrexon Corporation had its “buy” rating reaffirmed by analysts at Griffin Securities. They now have a $55.00 price target on the stock.
- 10/6/2017 – Intrexon Corporation had its “buy” rating reaffirmed by analysts at Northland Securities. They now have a $27.00 price target on the stock.
- 10/5/2017 – Intrexon Corporation had its “outperform” rating reaffirmed by analysts at JMP Securities. They now have a $42.00 price target on the stock.
Shares of Intrexon Corporation (NYSE XON) opened at 17.88 on Monday. The firm’s 50-day moving average price is $19.05 and its 200-day moving average price is $20.99. The stock’s market cap is $2.15 billion. Intrexon Corporation has a 52-week low of $17.03 and a 52-week high of $32.90.
Intrexon Corporation (NYSE:XON) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.05. Intrexon Corporation had a negative net margin of 60.63% and a negative return on equity of 19.08%. The business had revenue of $54.40 million for the quarter, compared to the consensus estimate of $57.17 million. During the same period in the prior year, the business posted ($0.42) earnings per share. Intrexon Corporation’s revenue for the quarter was up 3.6% compared to the same quarter last year. On average, equities research analysts forecast that Intrexon Corporation will post ($0.87) earnings per share for the current fiscal year.
In related news, CEO Randal J. Kirk purchased 132,625 shares of the company’s stock in a transaction dated Friday, August 11th. The shares were acquired at an average cost of $18.85 per share, with a total value of $2,499,981.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert B. Shapiro purchased 2,850 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The stock was bought at an average cost of $17.50 per share, for a total transaction of $49,875.00. Following the completion of the purchase, the director now directly owns 43,157 shares of the company’s stock, valued at approximately $755,247.50. The disclosure for this purchase can be found here. Insiders bought 144,569 shares of company stock worth $2,719,429 over the last ninety days. 55.10% of the stock is currently owned by company insiders.
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.